Table 1 Clinical characteristics of pediatric posterior fossa ependymoma
From: Characterization of global 5-hydroxymethylcytosine in pediatric posterior fossa ependymoma
Characteristics | Value (%) |
|---|---|
Demographics | |
 No. of patients | 45 |
 Age, years, median (range) | 4 (1–17) |
 Gender, (female/male) | 12/33 |
 Tumor size, cm, median (range) | 4.7 (2.3–19.5) |
 Extent of surgery, GTR, n (%) | 21 (46.7) |
 Radiotherapy, yes, n (%) | 29 (64.4) |
 Chemotherapy, yes, n (%) | 12 (26.7) |
Histology, n (%) | |
 WHO II | 10 (22.2) |
 WHO III | 35 (77.8) |
Ki-67 index, n (%) | |
 < 20% | 20 (44.4) |
 ≥ 20% | 25 (55.6) |
Molecular subgroups, n (%) | |
 EPN_PFA | 35 (77.8) |
 EPN_PFB | 10 (22.2) |
Chromosome 1q | |
 Gain | 16 (35.6) |
 No gain | 29 (64.4) |
5hmC/(C + mC) × 100%, median (range) | 0.127 (0.028–0.341) |
5mC/(C + mC) × 100%, mean ± SD | 3.664 ± 0.426 |
Recurrence, n (%) | 25 (55.6) |
Death during follow-up, n (%) | 23 (51.1) |
Follow-up period, months, median (range) | 38 (6–60) |